vs
Commercial Bancgroup, Inc.（CBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Commercial Bancgroup, Inc.的1.3倍（$30.3M vs $23.1M），Commercial Bancgroup, Inc.净利率更高（41.3% vs -221.3%，领先262.7%）
Commercial Bancgroup, Inc.是美国的一家区域性银行控股企业，为个人消费者、中小微企业及本地机构客户提供全品类零售与商业银行业务，核心服务涵盖存款账户、信贷产品、财富管理及定制化金融咨询方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CBK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.1M
净利率更高
CBK
高出262.7%
-221.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.1M | $30.3M |
| 净利润 | $9.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 41.3% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 9.7% | -31.2% |
| 每股收益（稀释后） | $0.69 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBKRGNX
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $30.3M | ||
| Q3 25 | $22.8M | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | — | $22.3M |
净利润CBKRGNX
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-67.1M | ||
| Q3 25 | $9.5M | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | — | $-53.0M |
毛利率CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -190.0% | ||
| Q3 25 | 53.8% | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% |
净利率CBKRGNX
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -221.3% | ||
| Q3 25 | 41.4% | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | — | -237.7% |
每股收益（稀释后）CBKRGNX
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-1.30 | ||
| Q3 25 | $0.77 | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $118.2M | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | $2.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | $154.8M | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
总债务CBKRGNX
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $102.7M | ||
| Q3 25 | $245.2M | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | — | $348.3M |
总资产CBKRGNX
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M |
负债/权益比CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $28.0M | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | — | $-45.5M |
自由现金流CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $26.5M | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M |
自由现金流率CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -174.0% | ||
| Q3 25 | 115.8% | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% |
资本支出强度CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.7% | ||
| Q3 25 | 6.7% | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% |
现金转化率CBKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
